Vemlidy vs. Truvada

Vemlidy (tenofovir alafenamide) and Truvada (emtricitabine/tenofovir disoproxil fumarate) are antiviral medications used to treat different conditions.

Vemlidy is used to treat chronic hepatitis B virus infection in adults with compensated liver disease.

Truvada is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). Truvada is not a cure for HIV or AIDS.

Side effects of Vemlidy and Truvada that are similar include headache, stomach/abdominal pain, nausea, and back pain.

Side effects of Vemlidy that are different from Truvada include fatigue and cough.

Side effects of Truvada that are different from Vemlidy include vomiting, diarrhea, dizziness, depression, joint pain, trouble sleeping, strange dreams, itching or skin rash, changes in the color of skin on your palms or soles of your feet, and changes in the shape or location of body fat (especially in your arms, legs, face, neck, breasts, and waist).

Both Vemlidy and Truvada may interact with antiviral medicines.

Vemlidy may also interact with drugs that induce P-gp activity, aminoglycosides, high-dose or multiple nonsteroidal anti-inflammatories (NSAIDs), anticonvulsants, antimycobacterials, and St. John's wort.

Truvada may also interact with lithium, methotrexate, pain or arthritis medicines, medicines used to prevent organ transplant rejection, IV antibiotics, cancer medicines, herpes medications, medications to treat cytomegalovirus (CMV), or other HIV medicines.

Common side effects of Vemlidy include:

• headache,
• abdominal pain,
• fatigue,
• cough,
• nausea, and
• back pain.

Common side effects of Truvada include:

• nausea,
• vomiting,
• stomach pain,
• diarrhea,
• headache,
• dizziness,
• depression,
• joint pain,
• trouble sleeping,
• strange dreams,
• back pain,
• itching or skin rash,
• changes in the color of skin on your palms or soles of your feet, or
• changes in the shape or location of body fat (especially in your arms, legs, face, neck, breasts, and waist).

Tell your doctor if you have serious side effects of Truvada including:

• mental/mood changes (such as depression, anxiety),
• loss of appetite,
• stomach or abdominal pain,
• pink or bloody urine, or
• changes in the amount of urine.

Vemlidy (tenofovir alafenamide) is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.

Truvada (emtricitabine/tenofovir disoproxil fumarate) is a combination of antiviral drugs used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). Truvada is not a cure for HIV or AIDS.

Vemlidy may interact with drugs that induce P-gp activity, antivirals, aminoglycosides, high-dose or multiple nonsteroidal anti-inflammatories (NSAIDs), anticonvulsants, antimycobacterials, and St. John's wort. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Vemlidy. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to during pregnancy. It is unknown if Vemlidy passes into breast milk. Consult your doctor before breastfeeding.

Truvada may interact with lithium, methotrexate, pain or arthritis medicines, medicines used to prevent organ transplant rejection, IV antibiotics, antiviral medicines, cancer medicines, herpes medications, medications to treat cytomegalovirus (CMV), or other HIV medicines. Tell your doctor all medications and supplements you use. During pregnancy, Truvada should be used only when prescribed. It is normal to prescribe HIV medicines such as Truvada for pregnant women with HIV. This can decrease the risk of passing HIV to the baby. Truvada may be part of that treatment. Consult your doctor. It is unknown if Truvada passes into breast milk. Because breast milk can transmit HIV, do not breastfeed.

The recommended dosage of Vemlidy is 25 mg (one tablet) taken orally once daily with food.

The dose of Truvada for adults and pediatric patients 12 years of age and older with body weight 35 kg (77 lb) or more is one tablet (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) once daily taken orally with or without food.